RxSight SG&A Expenses 2021-2024 | RXST

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

RxSight sg&a expenses from 2021 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

RxSight sg&a expenses from 2021 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$196.3B
Intuitive Surgical (ISRG)	$195.1B
Alcon (ALC)	$42.4B
Edwards Lifesciences (EW)	$41.6B
IQVIA Holdings (IQV)	$36.6B
IDEXX Laboratories (IDXX)	$34.2B
DexCom (DXCM)	$28.4B
Waters (WAT)	$22.2B
STERIS (STE)	$21.2B
SONOVA HOLDING (SONVY)	$20.8B
Hologic (HOLX)	$18.3B
Fresenius Medical Care AG KGaA (FMS)	$13B
Sysmex ADR (SSMXY)	$12.9B
Globus Medical (GMED)	$11.5B
Penumbra (PEN)	$9.4B
Masimo (MASI)	$9.3B
Teleflex (TFX)	$8.9B
Glaukos (GKOS)	$7.9B
PROCEPT BioRobotics (PRCT)	$4.9B
Integer Holdings (ITGR)	$4.6B
Veracyte (VCYT)	$3.1B
Inari Medical (NARI)	$2.9B
LivaNova (LIVN)	$2.8B
TransMedics (TMDX)	$2.6B
Nihon Kohden (NHNKY)	$2.5B
Elekta AB (EKTAY)	$2.2B
Tandem Diabetes Care (TNDM)	$2B
Integra LifeSciences Holdings (IART)	$1.8B
Alphatec Holdings (ATEC)	$1.4B
Artivion (AORT)	$1.2B